<article title='Acute_disseminated_encephalomyelitis'><paragraph><template><target>Use dmy dates</target><arg name="date">June 2013</arg></template><template><target>Infobox disease</target><arg name="Name"><space/>Acute disseminated encephalomyelitis
</arg><arg name="Image"><space/>
</arg><arg name="Caption"><space/>
</arg><arg name="DiseasesDB"><space/>158
</arg><arg name="ICD10"><space/>{{ICD10|G|04|0|g|00}} 
</arg><arg name="ICD9"><space/>{{ICD9|323.61}}, {{ICD9|323.81}}

</arg><arg name="ICDO"><space/>
</arg><arg name="OMIM"><space/>
</arg><arg name="MedlinePlus"><space/>
</arg><arg name="eMedicineSubj"><space/>neuro
</arg><arg name="eMedicineTopic"><space/>500
</arg><arg name="MeshID"><space/>D004673 
</arg></template><bold>Acute disseminated encephalomyelitis</bold><space/>(<bold>ADEM</bold>) (or acute demyelinating encephalomyelitis) is a rare<space/><link><target>autoimmune</target></link><space/>disease marked by a sudden, widespread attack of inflammation in the<space/><link><target>brain</target></link><space/>and<space/><link><target>spinal cord</target></link>. ADEM also attacks the nerves of the central nervous system and damages their myelin insulation, which, as a result, destroys the<space/><link><target>white matter</target></link>. It is often triggered after the patient has received a<space/><link><target>virus (biology)</target><part>viral</part></link><space/><link><target>infection</target></link><space/>or<space/><link><target>vaccination</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Dale RC<space/></arg><arg name="title">Acute disseminated encephalomyelitis<space/></arg><arg name="journal">Semin Pediatr Infect Dis<space/></arg><arg name="volume">14<space/></arg><arg name="issue">2<space/></arg><arg name="pages">90–5<space/></arg><arg name="date">April 2003<space/></arg><arg name="pmid">12881796<space/></arg><arg name="doi">10.1053/spid.2003.127225<space/></arg><arg name="url"></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Garg RK<space/></arg><arg name="title">Acute disseminated encephalomyelitis<space/></arg><arg name="journal">Postgrad Med J<space/></arg><arg name="volume">79<space/></arg><arg name="issue">927<space/></arg><arg name="pages">11–7<space/></arg><arg name="date">January 2003<space/></arg><arg name="pmid">12566545<space/></arg><arg name="doi"><space/>10.1136/pmj.79.927.11</arg><arg name="url">http://pmj.bmj.com/cgi/pmidlookup?view</arg><arg name="pmc">1742586</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Jones CT<space/></arg><arg name="title">Childhood autoimmune neurologic diseases of the central nervous system<space/></arg><arg name="journal">Neurol Clin<space/></arg><arg name="volume">21<space/></arg><arg name="issue">4<space/></arg><arg name="pages">745–64<space/></arg><arg name="date">November 2003<space/></arg><arg name="pmid">14743647<space/></arg><arg name="doi"><space/>10.1016/S0733-8619(03)00007-0</arg><arg name="url"></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Huynh W, Cordato DJ, Kehdi E, Masters LT, Dedousis C<space/></arg><arg name="title">Post-vaccination encephalomyelitis: literature review and illustrative case<space/></arg><arg name="journal">J Clin Neurosci<space/></arg><arg name="volume">15<space/></arg><arg name="issue">12<space/></arg><arg name="pages">:1315–1322<space/></arg><arg name="date">Dec 2008<space/></arg><arg name="pmid">18976924<space/></arg><arg name="doi">10.1016/j.jocn.2008.05.002<space/></arg><arg name="url"><space/></arg><arg name="last2">Cordato<space/></arg><arg name="last3">Kehdi<space/></arg><arg name="last4">Masters<space/></arg><arg name="last5">Dedousis<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Rust RS<space/></arg><arg name="title">Multiple sclerosis, acute disseminated encephalomyelitis, and related conditions<space/></arg><arg name="journal">Semin Pediatr Neurol<space/></arg><arg name="volume">7<space/></arg><arg name="issue">2<space/></arg><arg name="pages">66–90<space/></arg><arg name="date">June 2000<space/></arg><arg name="pmid">10914409<space/></arg><arg name="doi"><space/>10.1053/pb.2000.6693</arg><arg name="url"></arg></template></extension><extension extension_name='ref' name="Poser and Brinar 2007"><template><target>cite journal</target><arg name="author">Poser CM, Brinar VV<space/></arg><arg name="title">Disseminated encephalomyelitis and multiple sclerosis: two different diseases - a critical review<space/></arg><arg name="journal">Acta Neurol. Scand.<space/></arg><arg name="volume">116<space/></arg><arg name="issue">4<space/></arg><arg name="pages">201–6<space/></arg><arg name="date">October 2007<space/></arg><arg name="pmid">17824894<space/></arg><arg name="doi">10.1111/j.1600-0404.2007.00902.x<space/></arg><arg name="url"></arg><arg name="last2">Brinar<space/></arg></template></extension></paragraph><paragraph>ADEM's symptoms resemble the symptoms of<space/><link><target>multiple sclerosis</target></link><space/>(MS), so the disease itself is sorted into the classification of the<space/><link><target>multiple sclerosis borderline</target></link><space/>diseases. However, ADEM has several features that distinguish it from MS.<extension extension_name='ref'>Lauren B. Krupp et al. Consensus definitions proposed for pediatric multiple sclerosis and related disorders, 2007 by AAN Enterprises, Inc.<space/><link type='external' href='http://www.mc.vanderbilt.edu/documents/neurology/files/Consensus%20definitions%20proposed%20for%20pediatric%20multiple%20sclerosis%20and%20related%20disorders%20(International%20Pediatric%20MS%20Study%20Group,%20Neurology,%202007)(1).pdf'></link></extension><space/>Unlike MS, ADEM occurs usually in children and is marked with rapid fever, although adolescents and adults can get the disease too. ADEM consists of a single flare-up whereas MS is marked with several flare-ups over a long period of time. ADEM is also distinguished by a loss of consciousness, coma and death, which is very rare in MS, except in severe cases.</paragraph><paragraph>The incidence rate is about 8 per 1,000,000 people per year.<extension extension_name='ref' name="Leake et al. 2004"><template><target>cite journal</target><arg name="author">Leake JA, Albani S, Kao AS<space/></arg><arg name="title">Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features<space/></arg><arg name="journal">Pediatr. Infect. Dis. J.<space/></arg><arg name="volume">23<space/></arg><arg name="issue">8<space/></arg><arg name="pages">756–64<space/></arg><arg name="date">August 2004<space/></arg><arg name="pmid">15295226<space/></arg><arg name="doi"><space/>10.1097/01.inf.0000133048.75452.dd</arg><arg name="url">http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn</arg><arg name="author2">and others<space/></arg><arg name="displayauthors">1<space/></arg></template></extension><space/>Although it occurs in all ages, most reported cases are in children and<space/><link><target>Adolescence</target><part>adolescents</part></link>, with the average age around 5 to 8 years old.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Hynson JL, Kornberg AJ, Coleman LT, Shield L, Harvey AS, Kean MJ<space/></arg><arg name="title">Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children<space/></arg><arg name="journal">Neurology<space/></arg><arg name="volume">56<space/></arg><arg name="issue">10<space/></arg><arg name="pages">1308–12<space/></arg><arg name="date">May 2001<space/></arg><arg name="pmid">11376179<space/></arg><arg name="doi"><space/>10.1212/WNL.56.10.1308</arg><arg name="url">http://www.neurology.org/cgi/pmidlookup?view</arg><arg name="last2">Kornberg<space/></arg><arg name="last3">Coleman<space/></arg><arg name="last4">Shield<space/></arg><arg name="last5">Harvey<space/></arg><arg name="last6">Kean<space/></arg></template></extension><extension extension_name='ref' name="Anlar B, Basaran C, Kose G, et al. 2003 1949"><template><target>cite journal</target><arg name="author">Anlar B, Basaran C, Kose G<space/></arg><arg name="title">Acute disseminated encephalomyelitis in children: outcome and prognosis<space/></arg><arg name="journal">Neuropediatrics<space/></arg><arg name="volume">34<space/></arg><arg name="issue">4<space/></arg><arg name="pages">194–9<space/></arg><arg name="date">August 2003<space/></arg><arg name="pmid">12973660<space/></arg><arg name="doi">10.1055/s-2003-42208<space/></arg><arg name="url"></arg><arg name="author2">and others<space/></arg><arg name="displayauthors">1<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B<space/></arg><arg name="title">Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients<space/></arg><arg name="journal">Neurology<space/></arg><arg name="volume">56<space/></arg><arg name="issue">10<space/></arg><arg name="pages">1313–8<space/></arg><arg name="date">May 2001<space/></arg><arg name="pmid">11376180<space/></arg><arg name="doi"><space/>10.1212/WNL.56.10.1313</arg><arg name="url">http://www.neurology.org/cgi/pmidlookup?view</arg><arg name="last2">Mohr<space/></arg><arg name="last3">Knauth<space/></arg><arg name="last4">Wildemann<space/></arg><arg name="last5">Storch-Hagenlocher<space/></arg></template></extension><space/>The mortality rate may be as high as 5%; however, full recovery is seen in 50 to 75% of cases with increase in survival rates up to 70 to 90% with figures including minor residual disability as well.<extension extension_name='ref' name="Menge et al. 2007"><template><target>cite journal</target><arg name="author">Menge T, Kieseier BC, Nessler S, Hemmer B, Hartung HP, Stüve O<space/></arg><arg name="title">Acute disseminated encephalomyelitis: an acute hit against the brain<space/></arg><arg name="journal">Curr. Opin. Neurol.<space/></arg><arg name="volume">20<space/></arg><arg name="issue">3<space/></arg><arg name="pages">247–54<space/></arg><arg name="date">June 2007<space/></arg><arg name="pmid">17495616<space/></arg><arg name="doi">10.1097/WCO.0b013e3280f31b45<space/></arg><arg name="url"></arg><arg name="last2">Kieseier<space/></arg><arg name="last3">Nessler<space/></arg><arg name="last4">Hemmer<space/></arg><arg name="last5">Hartung<space/></arg><arg name="last6">Stüve<space/></arg></template></extension><space/>The average time to recover from ADEM flare-ups is one to six months.</paragraph><paragraph>ADEM produces multiple<space/><link><target>Inflammation</target><part>inflammatory</part></link><space/><link><target>lesion</target><trail>s</trail></link><space/>in the brain and<space/><link><target>spinal cord</target></link>, particularly in the<space/><link><target>white matter</target></link>. Usually these are found in the subcortical and central white matter and cortical gray-white junction of both<space/><link><target>cerebral hemispheres</target></link>,<space/><link><target>cerebellum</target></link>,<space/><link><target>brainstem</target></link>, and spinal cord,<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Wingerchuk DM<space/></arg><arg name="title">Postinfectious encephalomyelitis<space/></arg><arg name="journal">Curr Neurol Neurosci Rep<space/></arg><arg name="volume">3<space/></arg><arg name="issue">3<space/></arg><arg name="pages">256–64<space/></arg><arg name="date">May 2003<space/></arg><arg name="pmid">12691631<space/></arg><arg name="doi"><space/>10.1007/s11910-003-0086-x</arg><arg name="url"></arg></template></extension><space/>but periventricular white matter and gray matter of the<space/><link><target>Cerebral cortex</target><part>cortex</part></link>,<space/><link><target>thalami</target></link><space/>and<space/><link><target>basal ganglia</target></link><space/>may also be involved.</paragraph><paragraph>When the patient suffers more than one demyelinating episode of ADEM, the disease is then called<space/><bold>recurrent disseminated encephalomyelitis</bold><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Poser CM<space/></arg><arg name="title">Multiple sclerosis and recurrent disseminated encephalomyelitis are different diseases<space/></arg><arg name="journal">Arch. Neurol.<space/></arg><arg name="volume">65<space/></arg><arg name="issue">5<space/></arg><arg name="pages">674; author reply 674–5<space/></arg><arg name="date">May 2008<space/></arg><arg name="pmid">18474749<space/></arg><arg name="doi">10.1001/archneur.65.5.674-a<space/></arg><arg name="url"></arg></template></extension><space/>or<space/><bold>multiphasic disseminated encephalomyelitis</bold><extension extension_name='ref' name="Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG 2000 240722"><template><target>cite journal</target><arg name="author">Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG<space/></arg><arg name="title">Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children<space/></arg><arg name="journal">Brain<space/></arg><arg name="volume">123<space/></arg><arg name="issue"><space/>12</arg><arg name="pages">2407–22<space/></arg><arg name="date">December 2000<space/></arg><arg name="pmid">11099444<space/></arg><arg name="doi"><space/>10.1093/brain/123.12.2407</arg><arg name="url">http://brain.oxfordjournals.org/cgi/pmidlookup?view</arg><arg name="last2">De Sousa<space/></arg><arg name="last3">Chong<space/></arg><arg name="last4">Cox<space/></arg><arg name="last5">Harding<space/></arg><arg name="last6">Neville<space/></arg></template></extension>(MDEM).</paragraph><heading level='2'>Causes and antecedent history</heading><paragraph>Viral infections thought to induce ADEM include<space/><link><target>Orthomyxoviridae</target><part>influenza virus</part></link>,<space/><link><target>enterovirus</target></link>,<space/><link><target>measles</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Fisher<space/></arg><arg name="first">DL<space/></arg><arg name="last2">Defres<space/></arg><arg name="first2">S<space/></arg><arg name="last3">Solomon<space/></arg><arg name="first3">T</arg><arg name="title">Measles-induced encephalitis</arg><arg name="journal">QJM</arg><arg name="year">2015</arg><arg name="volume">108</arg><arg name="issue">3<space/></arg><arg name="pmid">24865261</arg><arg name="url">http://www.ncbi.nlm.nih.gov/pubmed/24865261</arg><arg name="doi">10.1093/qjmed/hcu113<space/></arg><arg name="pages">177–182</arg></template></extension><space/><link><target>mumps</target></link>,<space/><link><target>rubella</target></link>,<space/><link><target>varicella zoster</target></link>,<space/><link><target>Epstein Barr virus</target></link>,<space/><link><target>cytomegalovirus</target></link>,<space/><link><target>herpes simplex virus</target></link>,<space/><link><target>hepatitis A</target></link>, and<space/><link><target>coxsackievirus</target></link>; while the bacterial infections include<space/><link><target>Mycoplasma pneumoniae</target></link>,<space/><link><target>Borrelia burgdorferi</target></link>,<space/><link><target>Leptospira</target></link>, and<space/><link><target>Streptococcus#Beta-Hemolytic Streptococci</target><part>beta-hemolytic Streptococci</part></link>.<extension extension_name='ref' name="Tenembaum et al. 2007"><template><target>cite journal</target><arg name="author">Tenembaum S, Chitnis T, Ness J, Hahn JS<space/></arg><arg name="title">Acute disseminated encephalomyelitis<space/></arg><arg name="journal">Neurology<space/></arg><arg name="volume">68<space/></arg><arg name="issue">16 Suppl 2<space/></arg><arg name="pages">S23–36<space/></arg><arg name="date">April 2007<space/></arg><arg name="pmid">17438235<space/></arg><arg name="doi">10.1212/01.wnl.0000259404.51352.7f<space/></arg><arg name="url"></arg><arg name="last2">Chitnis<space/></arg><arg name="last3">Ness<space/></arg><arg name="last4">Hahn<space/></arg><arg name="author5">International Pediatric MS Study Group<space/></arg></template></extension><space/>The only vaccine proven to induce ADEM is the Semple form of the<space/><link><target>rabies</target></link><space/>vaccine, but<space/><link><target>hepatitis B</target></link>,<space/><link><target>pertussis</target></link>,<space/><link><target>diphtheria</target></link>, measles, mumps, rubella,<space/><link><target>pneumococcus</target></link>,<space/><link><target>varicella</target></link>, influenza,<space/><link><target>Japanese encephalitis</target></link>, and<space/><link><target>polio</target></link><space/>vaccines have all been implicated. The majority of the studies that correlate vaccination with ADEM onset use small samples or case studies<template><target>citation needed</target><arg name="date">August 2014</arg></template>. Large scale epidemiological studies (e.g., of MMR vaccine or smallpox vaccine) do not show increased risk of ADEM following vaccination.<extension extension_name='ref' name="Leake et al. 2004"></extension><extension extension_name='ref' name="Hemachudha T, Griffin DE, Giffels JJ, Johnson RT, Moser AB, Phanuphak P 1987 36974"><template><target>cite journal</target><arg name="author">Hemachudha T, Griffin DE, Giffels JJ, Johnson RT, Moser AB, Phanuphak P<space/></arg><arg name="title">Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination<space/></arg><arg name="journal">N. Engl. J. Med.<space/></arg><arg name="volume">316<space/></arg><arg name="issue">7<space/></arg><arg name="pages">369–74<space/></arg><arg name="date">February 1987<space/></arg><arg name="pmid">2433582<space/></arg><arg name="doi"><space/>10.1056/NEJM198702123160703</arg><arg name="url"></arg><arg name="last2">Griffin<space/></arg><arg name="last3">Giffels<space/></arg><arg name="last4">Johnson<space/></arg><arg name="last5">Moser<space/></arg><arg name="last6">Phanuphak<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Hemachudha T, Griffin DE, Johnson RT, Giffels JJ<space/></arg><arg name="title">Immunologic studies of patients with chronic encephalitis induced by post-exposure Semple rabies vaccine<space/></arg><arg name="journal">Neurology<space/></arg><arg name="volume">38<space/></arg><arg name="issue">1<space/></arg><arg name="pages">42–4<space/></arg><arg name="date">January 1988<space/></arg><arg name="pmid">2447520<space/></arg><arg name="doi"><space/>10.1212/WNL.38.1.42</arg><arg name="url"></arg><arg name="last2">Griffin<space/></arg><arg name="last3">Johnson<space/></arg><arg name="last4">Giffels<space/></arg></template></extension><extension extension_name='ref' name="Murthy 2002"><template><target>cite journal</target><arg name="author">Murthy JM<space/></arg><arg name="title">Acute disseminated encephalomyelitis<space/></arg><arg name="journal">Neurol India<space/></arg><arg name="volume">50<space/></arg><arg name="issue">3<space/></arg><arg name="pages">238–43<space/></arg><arg name="date">September 2002<space/></arg><arg name="pmid">12391446<space/></arg><arg name="doi"><space/></arg><arg name="url">http://www.neurologyindia.com/article.asp?issn</arg></template></extension><extension extension_name='ref' name="Tenembaum et al. 2002"><template><target>cite journal</target><arg name="author">Tenembaum S, Chamoles N, Fejerman N<space/></arg><arg name="title">Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients<space/></arg><arg name="journal">Neurology<space/></arg><arg name="volume">59<space/></arg><arg name="issue">8<space/></arg><arg name="pages">1224–31<space/></arg><arg name="date">October 2002<space/></arg><arg name="pmid">12391351<space/></arg><arg name="doi"><space/>10.1212/WNL.59.8.1224</arg><arg name="url">http://www.neurology.org/cgi/pmidlookup?view</arg><arg name="last2">Chamoles<space/></arg><arg name="last3">Fejerman<space/></arg></template></extension><extension extension_name='ref' name="Fenichel 1982"><template><target>cite journal</target><arg name="author">Fenichel GM<space/></arg><arg name="title">Neurological complications of immunization<space/></arg><arg name="journal">Ann. Neurol.<space/></arg><arg name="volume">12<space/></arg><arg name="issue">2<space/></arg><arg name="pages">119–28<space/></arg><arg name="date">August 1982<space/></arg><arg name="pmid">6751212<space/></arg><arg name="doi">10.1002/ana.410120202<space/></arg><arg name="url"></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Takahashi H, Pool V, Tsai1 TF, Chen RT<space/></arg><arg name="title">Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group<space/></arg><arg name="journal">Vaccine<space/></arg><arg name="volume">18<space/></arg><arg name="issue">26<space/></arg><arg name="pages">2963–9<space/></arg><arg name="date">July 2000<space/></arg><arg name="pmid">10825597<space/></arg><arg name="doi"><space/>10.1016/S0264-410X(00)00111-0</arg><arg name="url">http://linkinghub.elsevier.com/retrieve/pii/S0264410X00001110</arg><arg name="last2">Pool<space/></arg><arg name="last3">Tsai<space/></arg><arg name="last4">Chen<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Tourbah A, Gout O, Liblau R<space/></arg><arg name="title">Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS?<space/></arg><arg name="journal">Neurology<space/></arg><arg name="volume">53<space/></arg><arg name="issue">2<space/></arg><arg name="pages">396–401<space/></arg><arg name="date">July 1999<space/></arg><arg name="pmid">10430433<space/></arg><arg name="doi"><space/>10.1212/WNL.53.2.396</arg><arg name="url">http://www.neurology.org/cgi/pmidlookup?view</arg><arg name="author2">and others<space/></arg><arg name="displayauthors">1<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Karaali-Savrun F, Altintaş A, Saip S, Siva A<space/></arg><arg name="title">Hepatitis B vaccine related-myelitis?<space/></arg><arg name="journal">Eur. J. Neurol.<space/></arg><arg name="volume">8<space/></arg><arg name="issue">6<space/></arg><arg name="pages">711–5<space/></arg><arg name="date">November 2001<space/></arg><arg name="pmid">11784358<space/></arg><arg name="doi"><space/>10.1046/j.1468-1331.2001.00290.x</arg><arg name="url">http://www.blackwell-synergy.com/openurl?genre</arg><arg name="last2">Altintaş<space/></arg><arg name="last3">Saip<space/></arg><arg name="last4">Siva<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Sejvar JJ, Labutta RJ, Chapman LE, Grabenstein JD, Iskander J, Lane JM<space/></arg><arg name="title">Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004<space/></arg><arg name="journal">JAMA<space/></arg><arg name="volume">294<space/></arg><arg name="issue">21<space/></arg><arg name="pages">2744–50<space/></arg><arg name="date">December 2005<space/></arg><arg name="pmid">16333010<space/></arg><arg name="doi">10.1001/jama.294.21.2744<space/></arg><arg name="url"></arg><arg name="last2">Labutta<space/></arg><arg name="last3">Chapman<space/></arg><arg name="last4">Grabenstein<space/></arg><arg name="last5">Iskander<space/></arg><arg name="last6">Lane<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Ozawa H, Noma S, Yoshida Y, Sekine H, Hashimoto T<space/></arg><arg name="title">Acute disseminated encephalomyelitis associated with poliomyelitis vaccine<space/></arg><arg name="journal">Pediatr. Neurol.<space/></arg><arg name="volume">23<space/></arg><arg name="issue">2<space/></arg><arg name="pages">177–9<space/></arg><arg name="date">August 2000<space/></arg><arg name="pmid">11020647<space/></arg><arg name="doi"><space/>10.1016/S0887-8994(00)00167-3</arg><arg name="url">http://linkinghub.elsevier.com/retrieve/pii/S0887-8994(00)00167-3</arg><arg name="last2">Noma<space/></arg><arg name="last3">Yoshida<space/></arg><arg name="last4">Sekine<space/></arg><arg name="last5">Hashimoto<space/></arg></template></extension><space/>In rare cases, ADEM seems to follow from<space/><link><target>organ transplant</target><trail>ation</trail></link>.<extension extension_name='ref' name="Tenembaum et al. 2002"></extension><space/>The risk of ADEM from measles vaccination is about 1 to 2 per million,<extension extension_name='ref' name="Murthy 2002"></extension><space/>which is far lower than the risk of developing ADEM from an actual measles infection, which is about 1 per 1000 for measles (and 1 per 5000 for rubella).<extension extension_name='ref' name="Fenichel 1982"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Miller HG, Stanton JB, Gibbons JL<space/></arg><arg name="title">Parainfectious encephalomyelitis and related syndromes<space/></arg><arg name="journal">Quarterly Journal of Medicine<space/></arg><arg name="volume">25<space/></arg><arg name="issue"><space/>100</arg><arg name="pages">427–505<space/></arg><arg name="year">1956<space/></arg><arg name="pmid">13379602</arg></template></extension><space/>Some vaccines, later shown to have been contaminated with host animal<space/><link><target>Central nervous system</target><part>CNS</part></link><space/>tissue, have ADEM incident rates as high as 1 in 600.<extension extension_name='ref' name="Hemachudha T, Griffin DE, Giffels JJ, Johnson RT, Moser AB, Phanuphak P 1987 36974"></extension></paragraph><heading level='2'>Presentation</heading><paragraph>ADEM has an abrupt onset and a monophasic course. Symptoms usually begin 13 weeks after infection. Major symptoms include<space/><link><target>fever</target></link>,<space/><link><target>headache</target></link>,<space/><link><target>nausea</target></link><space/>and<space/><link><target>vomiting</target></link>,<space/><link><target>confusion</target></link>,<space/><link><target>Blindness</target><part>vision impairment</part></link>, drowsiness,<space/><link><target>non-epileptic seizure</target><part>seizure</part><trail>s</trail></link><space/>and<space/><link><target>coma</target></link>. Although initially the symptoms are usually mild, they worsen rapidly over the course of hours to days, with the average time to maximum severity being about four and a half days.<extension extension_name='ref' name="Tenembaum et al. 2002"></extension><space/>Additional symptoms include hemiparesis, paraparesis, and cranial nerve palsies.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Allmendinger A, Krauthamer A, Spektor V<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="title"><space/>Case of the month<space/></arg><arg name="url"><space/>http://www.diagnosticimaging.com/case-studies/content/article/113619/1493546<space/></arg><arg name="journal"><space/>Diagnostic Imaging<space/></arg><arg name="volume"><space/>31<space/></arg><arg name="issue"><space/>12</arg><arg name="page"><space/>10<space/></arg></template></extension></paragraph><heading level='2'>Treatment</heading><paragraph>No controlled clinical trials have been conducted on ADEM treatment, but aggressive treatment aimed at rapidly reducing inflammation of the CNS is standard. The widely accepted<space/><link><target>first-line treatment</target></link><space/>is high doses of intravenous<space/><link><target>corticosteroid</target><trail>s</trail></link>,<extension extension_name='ref' name="Shahar et al. 2002"></extension><space/>such as<space/><link><target>methylprednisolone</target></link><space/>or<space/><link><target>dexamethasone</target></link>, followed by 36 weeks of gradually lower oral doses of<space/><link><target>prednisolone</target></link>. Patients treated with methylprednisolone have shown better outcomes than those treated with dexamethasone.<extension extension_name='ref' name="Tenembaum et al. 2002"></extension><space/>Oral tapers of less than three weeks duration show a higher chance of relapsing,<extension extension_name='ref' name="Anlar B, Basaran C, Kose G, et al. 2003 1949"></extension><extension extension_name='ref' name="Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG 2000 240722"></extension><space/>and tend to show poorer outcomes.<template><target>citation needed</target><arg name="date">March 2008</arg></template><space/>Other anti-inflammatory and immunosuppressive therapies have been reported to show beneficial effect, such as<space/><link><target>plasmapheresis</target></link>, high doses of intravenous<space/><link><target>immunoglobulin</target></link><space/>(IVIg),<extension extension_name='ref' name="Shahar et al. 2002"><template><target>cite journal</target><arg name="author">Shahar E, Andraus J, Savitzki D, Pilar G, Zelnik N<space/></arg><arg name="title">Outcome of severe encephalomyelitis in children: effect of high-dose methylprednisolone and immunoglobulins<space/></arg><arg name="journal">J. Child Neurol.<space/></arg><arg name="volume">17<space/></arg><arg name="issue">11<space/></arg><arg name="pages">810–4<space/></arg><arg name="date">November 2002<space/></arg><arg name="pmid">12585719<space/></arg><arg name="doi"><space/>10.1177/08830738020170111001</arg><arg name="url"></arg></template></extension><extension extension_name='ref' name="Ravaglia S, Piccolo G, Ceroni M, et al. 2007 151823"><template><target>cite journal</target><arg name="author">Ravaglia S, Piccolo G, Ceroni M<space/></arg><arg name="title">Severe steroid-resistant post-infectious encephalomyelitis: general features and effects of IVIg<space/></arg><arg name="journal">J. Neurol.<space/></arg><arg name="volume">254<space/></arg><arg name="issue">11<space/></arg><arg name="pages">1518–23<space/></arg><arg name="date">November 2007<space/></arg><arg name="pmid">17965959<space/></arg><arg name="doi">10.1007/s00415-007-0561-4<space/></arg><arg name="url"></arg><arg name="display-authors">etal</arg></template></extension><space/><link><target>mitoxantrone</target></link><space/>and<space/><link><target>cyclophosphamide</target></link>. These are considered alternative therapies, used when corticosteroids cannot be used, or fail to show an effect.</paragraph><paragraph>There is some evidence to suggest that patients may respond to a combination of methylprednisolone and immunoglobulins if they fail to respond to either separately<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Straussberg R, Schonfeld T, Weitz R, Karmazyn B, Harel L<space/></arg><arg name="title">Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins<space/></arg><arg name="journal">Pediatr. Neurol.<space/></arg><arg name="volume">24<space/></arg><arg name="issue">2<space/></arg><arg name="pages">139–43<space/></arg><arg name="date">February 2001<space/></arg><arg name="pmid">11275464<space/></arg><arg name="doi"><space/>10.1016/S0887-8994(00)00229-0</arg><arg name="url">http://linkinghub.elsevier.com/retrieve/pii/S0887-8994(00)00229-0</arg></template></extension>In a study of 16 children with ADEM, 10 recovered completely after high-dose methylprednisolone, one severe case that failed to respond to steroids recovered completely after IV Ig; the five most severe cases -with ADAM and severe<space/><link><target>peripheral neuropathy</target></link>- were treated with combined high-dose methylprednisolone and immunoglobulin, two remained paraplegic, one had motor and cognitive handicaps, and two recovered.<extension extension_name='ref' name="Shahar et al. 2002"></extension><space/>A recent review of IVIg treatment of ADEM (of which the previous study formed the bulk of the cases) found that 70% of children showed complete recovery after treatment with IVIg, or IVIg plus corticosteroids.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Feasby T, Banwell B, Benstead T<space/></arg><arg name="title">Guidelines on the use of intravenous immune globulin for neurologic conditions<space/></arg><arg name="journal">Transfus Med Rev<space/></arg><arg name="volume">21<space/></arg><arg name="issue">2 Suppl 1<space/></arg><arg name="pages">S57–107<space/></arg><arg name="date">April 2007<space/></arg><arg name="pmid">17397768<space/></arg><arg name="doi">10.1016/j.tmrv.2007.01.002<space/></arg><arg name="url"></arg><arg name="display-authors">etal</arg></template></extension><space/>A study of IVIg treatment in adults with ADEM showed that IVIg seems more effective in treating sensory and motor disturbances, while steroids seem more effective in treating impairments of cognition, consciousness and rigor.<extension extension_name='ref' name="Ravaglia S, Piccolo G, Ceroni M, et al. 2007 151823"></extension><space/>This same study found one subject, a 71-year-old man who had not responded to steroids, that responded to an IVIg treatment 58 days after disease onset.</paragraph><heading level='2'>Prognosis</heading><paragraph>Full recovery is seen in 50 to 70% of cases, ranging to 70 to 90% recovery with some minor residual disability (typically assessed using measures such as<space/><link><target>Modified Rankin Scale</target><part>mRS</part></link><space/>or<space/><link><target>Expanded Disability Status Scale</target><part>EDSS</part></link>), average time to recover is one to six months.<extension extension_name='ref' name="Menge et al. 2007"></extension><space/>The mortality rate may be as high as 5%.<extension extension_name='ref' name="Menge et al. 2007"></extension><space/>Poorer outcomes are associated with unresponsiveness to steroid therapy, unusually severe neurological symptoms, or sudden onset. Children tend to have more favorable outcomes than adults, and cases presenting without fevers tend to have poorer outcomes.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Lin CH, Jeng JS, Hsieh ST, Yip PK, Wu RM<space/></arg><arg name="title">Acute disseminated encephalomyelitis: a follow-up study in Taiwan<space/></arg><arg name="journal">J. Neurol. Neurosurg. Psychiatr.<space/></arg><arg name="volume">78<space/></arg><arg name="issue">2<space/></arg><arg name="pages">162–7<space/></arg><arg name="date">February 2007<space/></arg><arg name="pmid">17028121<space/></arg><arg name="doi">10.1136/jnnp.2005.084194<space/></arg><arg name="pmc">2077670</arg></template></extension><space/>The latter effect may be due to either protective effects of fever, or that diagnosis and treatment is sought more rapidly when fever is present.</paragraph><heading level='3'>Motor deficits</heading><paragraph>Residual motor deficits are estimated to remain in about 8 to 30% of cases, the range in severity from mild clumsiness to<space/><link><target>ataxia</target></link><space/>and<space/><link><target>hemiparesis</target></link>.<extension extension_name='ref' name="Tenembaum et al. 2007"></extension></paragraph><heading level='3'>Neurocognitive</heading><paragraph>Patients with demyelinating illnesses, such as MS, have shown cognitive deficits even when there is minimal physical disability.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Foong J, Rozewicz L, Quaghebeur G<space/></arg><arg name="title">Executive function in multiple sclerosis. The role of frontal lobe pathology<space/></arg><arg name="journal">Brain<space/></arg><arg name="volume">120<space/></arg><arg name="issue"><space/>1</arg><arg name="pages">15–26<space/></arg><arg name="date">January 1997<space/></arg><arg name="pmid">9055794<space/></arg><arg name="doi"><space/>10.1093/brain/120.1.15</arg><arg name="url">http://brain.oxfordjournals.org/cgi/pmidlookup?view</arg><arg name="display-authors">etal</arg></template></extension><space/>Research suggests that similar effects are seen after ADEM, but that the deficits are less severe than those seen in MS. A study of six children with ADEM (mean age at presentation 7.7 years) were tested for a range of neurocognitive tests after an average of 3.5 years of recovery.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Hahn CD, Miles BS, MacGregor DL, Blaser SI, Banwell BL, Hetherington CR<space/></arg><arg name="title">Neurocognitive outcome after acute disseminated encephalomyelitis<space/></arg><arg name="journal">Pediatr. Neurol.<space/></arg><arg name="volume">29<space/></arg><arg name="issue">2<space/></arg><arg name="pages">117–23<space/></arg><arg name="date">August 2003<space/></arg><arg name="pmid">14580654<space/></arg><arg name="doi"><space/>10.1016/S0887-8994(03)00143-7</arg><arg name="url">http://linkinghub.elsevier.com/retrieve/pii/S0887899403001437</arg></template></extension><space/>All six children performed in the normal range on most tests, including<space/><link><target>Wechsler Adult Intelligence Scale#Verbal Subtests</target><part>verbal IQ</part></link><space/>and<space/><link><target>Wechsler Adult Intelligence Scale#Performance Subtests</target><part>performance IQ</part></link>, but performed at least one<space/><link><target>standard deviation</target></link><space/>below age norms in at least one cognitive domain, such as complex attention (one child),<space/><link><target>Wechsler Adult Intelligence Scale#Working memory</target><part>short-term memory</part></link><space/>(one child) and internalizing behaviour/<link><target>Affect (psychology)</target><part>affect</part></link><space/>(two children). Group means for each cognitive domain were all within one standard deviation of age norms, demonstrating that, as a group, they were normal. These deficits were less severe than those seen in similar aged children with a diagnosis of MS.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Banwell BL, Anderson PE<space/></arg><arg name="title">The cognitive burden of multiple sclerosis in children<space/></arg><arg name="journal">Neurology<space/></arg><arg name="volume">64<space/></arg><arg name="issue">5<space/></arg><arg name="pages">891–4<space/></arg><arg name="date">March 2005<space/></arg><arg name="pmid">15753431<space/></arg><arg name="doi">10.1212/01.WNL.0000152896.35341.51<space/></arg></template></extension></paragraph><paragraph>Another study compared nineteen children with a history of ADEM, of which 10 were five years of age or younger at the time (average age 3.8 years old, tested an average of 3.9 years later) and nine were older (mean age 7.7y at time of ADEM, tested an average of 2.2 years later) to nineteen matched controls.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Jacobs RK, Anderson VA, Neale JL, Shield LK, Kornberg AJ<space/></arg><arg name="title">Neuropsychological outcome after acute disseminated encephalomyelitis: impact of age at illness onset<space/></arg><arg name="journal">Pediatr. Neurol.<space/></arg><arg name="volume">31<space/></arg><arg name="issue">3<space/></arg><arg name="pages">191–7<space/></arg><arg name="date">September 2004<space/></arg><arg name="pmid">15351018<space/></arg><arg name="doi">10.1016/j.pediatrneurol.2004.03.008<space/></arg><arg name="url"></arg></template></extension><space/>Scores on IQ tests and educational achievement were lower for the young onset ADEM group (average IQ 90) compared to the late onset (average IQ 100) and control groups (average IQ 106), while the late onset ADEM children scored lower on verbal processing speed. Again, all groups means were within one standard deviation of the controls, meaning that while effects were statistically reliable, the children were as a whole, still within the normal range. There were also more behavioural problems in the early onset group, although there is some suggestion that this may be due, at least in part, to the stress of hospitalization at a young age.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Douglas JW<space/></arg><arg name="title">Early hospital admissions and later disturbances of behaviour and learning<space/></arg><arg name="journal">Dev Med Child Neurol<space/></arg><arg name="volume">17<space/></arg><arg name="issue">4<space/></arg><arg name="pages">456–80<space/></arg><arg name="date">August 1975<space/></arg><arg name="pmid">1158052<space/></arg><arg name="doi"><space/>10.1111/j.1469-8749.1975.tb03497.x</arg><arg name="url"></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Daviss WB, Racusin R, Fleischer A, Mooney D, Ford JD, McHugo GJ<space/></arg><arg name="title">Acute stress disorder symptomatology during hospitalization for pediatric injury<space/></arg><arg name="journal">J Am Acad Child Adolesc Psychiatry<space/></arg><arg name="volume">39<space/></arg><arg name="issue">5<space/></arg><arg name="pages">569–75<space/></arg><arg name="date">May 2000<space/></arg><arg name="pmid">10802974<space/></arg><arg name="doi"><space/>10.1097/00004583-200005000-00010</arg><arg name="url">http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn</arg></template></extension></paragraph><heading level='2'>Acute disseminated encephalomyelitis and multiple sclerosis</heading><paragraph>While ADEM and MS both involve autoimmune demyelination, they differ in many clinical, genetic, imaging, and histopathological aspects.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Wingerchuk DM, Lucchinetti CF<space/></arg><arg name="title">Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis<space/></arg><arg name="journal">Curr. Opin. Neurol.<space/></arg><arg name="volume">20<space/></arg><arg name="issue">3<space/></arg><arg name="pages">343–50<space/></arg><arg name="date">June 2007<space/></arg><arg name="pmid">17495631<space/></arg><arg name="doi">10.1097/WCO.0b013e3280be58d8<space/></arg><arg name="url"></arg></template></extension><space/>Some authors consider MS and its<space/><link><target>Idiopathic inflammatory demyelinating diseases</target><part>borderline forms</part></link><space/>to constitute a spectrum, differing only in chronicity, severity, and clinical course,<extension extension_name='ref'>Weinshenker B, Miller D. (1999). Multiple sclerosis: one disease or many? In: Siva A, Kesselring J, Thompson A, eds. Frontiers in multiple sclerosis. London: Dunitz, p37-46.</extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Hartung HP, Grossman RI<space/></arg><arg name="title">ADEM: distinct disease or part of the MS spectrum?<space/></arg><arg name="journal">Neurology<space/></arg><arg name="volume">56<space/></arg><arg name="issue">10<space/></arg><arg name="pages">1257–60<space/></arg><arg name="date">May 2001<space/></arg><arg name="pmid">11376169<space/></arg><arg name="doi"><space/>10.1212/WNL.56.10.1257</arg><arg name="url">http://www.neurology.org/cgi/pmidlookup?view</arg></template></extension><space/>while others consider them discretely different diseases.<extension extension_name='ref' name="Poser and Brinar 2007"></extension></paragraph><paragraph>Normally ADEM appears in children after a vaccination and it is monophasic. Nevertheless, ADEM can appear in adults, and can also be clinically multiphasic.<extension extension_name='ref'>Lauren B. Krupp et al, Consensus definitions proposed forpediatric multiple sclerosis and related disorders. NEUROLOGY 2007;68(Suppl 2):S7S12</extension></paragraph><paragraph>Problems for differential diagnosis increase due to the lack of agreement for a definition of Multiple Sclerosis.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lassmann H<space/></arg><arg name="year"><space/></arg><arg name="title"><space/>Acute disseminated encephalomyelitis and multiple sclerosis<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Brain<space/></arg><arg name="volume"><space/>133<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>317–319<space/></arg><arg name="doi"><space/>10.1093/brain/awp342<space/></arg></template></extension><space/>For some people MS should be considered a clinical entity based in inflammatory lesions separated in time and space.<extension extension_name='ref' name="pmid11456302"><template><target>cite journal</target><arg name="author">McDonald WI, Compston A, Edan G<space/></arg><arg name="title">Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis</arg><arg name="url"></arg><arg name="journal">[[Ann. Neurol.]]<space/></arg><arg name="volume">50<space/></arg><arg name="issue">1<space/></arg><arg name="pages">121–7<space/></arg><arg name="year">2001<space/></arg><arg name="pmid">11456302<space/></arg><arg name="doi"><space/>10.1002/ana.1032</arg><arg name="display-authors">etal</arg></template></extension><space/>As some cases of ADEM satisfy these conditions, they can be considered inside the clinical MS spectrum.</paragraph><paragraph>The pathology of ADEM is very similar to that of MS with some differences. The pathological hallmark of ADEM is perivenular inflammation with limited sleeves of demyelination..<extension extension_name='ref'>Nathan P. Young, Acute Disseminated Encephalomyelitis: Current Understanding and Controversies. Thieme Medical Publishers (Semin Neurol. 2008 Feb;28(1):84-94)<space/><link type='external' href='https://www.orpha.net/data/patho/Pro/en/AcuteDisseminatedEncephalomyelitisr-FRenPro11590v01.pdf'></link></extension></paragraph><paragraph>Plaques in the white matter in MS are sharply delineated, while the<space/><link><target>glial scar</target></link><space/>in ADEM is smooth. Axons are better preserved in ADEM lesions. Inflammation in ADEM is widely disseminated and ill-defined, and finally, lesions are strictly perivenous, while in MS they are disposed around veins, but not so sharply.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lu Z, Zhang B, Qiu W, Kang Z, Shen L<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="title"><space/>Comparative Brain Stem Lesions on MRI of Acute Disseminated Encephalomyelitis, Neuromyelitis Optica, and Multiple Sclerosis<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>PLoS ONE<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>8</arg><arg name="page"><space/>e22766<space/></arg><arg name="doi"><space/>10.1371/journal.pone.0022766<space/></arg><arg name="display-authors">etal</arg></template></extension></paragraph><paragraph>Nevertheless, the co-occurrence of perivenous and confluent demyelination in some individuals suggests pathogenic overlap between acute disseminated encephalomyelitis and multiple sclerosis and misclassification even with biopsy<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Nathan P.<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="title"><space/>Young ''et al.'' Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Brain<space/></arg><arg name="volume"><space/>133</arg><arg name="issue"><space/></arg><arg name="pages"><space/>333–348<space/></arg><arg name="doi"><space/>10.1093/brain/awp321<space/></arg><arg name="display-authors">etal</arg></template></extension><space/>or even postmortem<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Guenther AD, Munoz DG<space/></arg><arg name="year"><space/>2013<space/></arg><arg name="title"><space/>Plaque-like demyelination in acute disseminated encephalomyelitis (ADEM) - an autopsy case report<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Clinical Neuropathology<space/></arg><arg name="volume"><space/>32<space/></arg><arg name="issue"><space/>6</arg><arg name="pages"><space/>486–491<space/></arg><arg name="doi"><space/>10.5414/NP300634<space/></arg><arg name="pmid"><space/>23863345<space/></arg></template></extension><space/></paragraph><heading level='2'>Multiphasic disseminated encephalomyelitis</heading><paragraph>When the patient suffers more than one demyelinating episode of ADEM, the disease is then called<space/><bold>recurrent disseminated encephalomyelitis</bold><space/>or<space/><bold>multiphasic disseminated encephalomyelitis</bold><extension extension_name='ref' name="Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG 2000 240722"></extension><space/>(MDEM).</paragraph><paragraph>It has been found that anti-<link><target>Myelin oligodendrocyte glycoprotein</target><part>MOG</part></link><space/>auto-antibodies are related to this kind of ADEM<extension extension_name='ref'>M. Baumann, E.M. Hennes, K. Schanda, M. Karenfort, B. Bajer-Kornek, K. Diepold, B. Fiedler, I. Marquardt, J. Strautmanis, S. Vieker, M. Reindl, K. Rostsy. Clinical characteristics and neuroradiological findings in children with multiphasic demyelinating encephalomyelitis and MOG antibodies. European Journal of Paediatric Neurology, Volume 19, Supplement 1, May 2015, Pages S21, Abstracts of the 11th EPNS Congress. 22 May 2015. doi:10.1016/S1090-3798(15)30066-0</extension></paragraph><heading level='2'>Acute hemorrhagic leukoencephalitis</heading><paragraph>Acute hemorrhagic leukoencephalitis (AHL, or AHLE), also known as acute necrotizing encephalopathy (ANE), acute hemorrhagic encephalomyelitis (AHEM), acute necrotizing hemorrhagic leukoencephalitis (ANHLE), Weston-Hurst syndrome, or Hurst's disease, is a hyperacute and frequently fatal form of ADEM. AHL is relatively rare (less than 100 cases have been reported in the medical literature<space/><template><target>as of</target><arg>2006</arg><arg name="lc">y</arg></template>),<extension extension_name='ref' name="Davies et al. 2006"><template><target>cite journal</target><arg name="author">Davies NW, Sharief MK, Howard RS<space/></arg><arg name="title">Infection-associated encephalopathies: their investigation, diagnosis, and treatment<space/></arg><arg name="journal">J. Neurol.<space/></arg><arg name="volume">253<space/></arg><arg name="issue">7<space/></arg><arg name="pages">833–45<space/></arg><arg name="date">July 2006<space/></arg><arg name="pmid">16715200<space/></arg><arg name="doi">10.1007/s00415-006-0092-4<space/></arg><arg name="url"></arg><arg name="last2">Sharief<space/></arg><arg name="last3">Howard<space/></arg></template></extension><space/>it is seen in about 2% of ADEM cases,<extension extension_name='ref' name="Tenembaum et al. 2002"></extension><space/>and is characterized by<space/><link><target>necrosis</target><part>necrotizing vasculitis</part></link><space/>of<space/><link><target>venules</target></link><space/>and hemorrhage, and edema.<extension extension_name='ref' name="Stone &amp; Hawkins 2007"><template><target>cite journal</target><arg name="author">Stone MJ, Hawkins CP<space/></arg><arg name="title">A medical overview of encephalitis<space/></arg><arg name="journal">Neuropsychol Rehabil<space/></arg><arg name="volume">17<space/></arg><arg name="issue">4–5<space/></arg><arg name="pages">429–49<space/></arg><arg name="year">2007<space/></arg><arg name="pmid">17676529<space/></arg><arg name="doi">10.1080/09602010601069430<space/></arg><arg name="url"></arg><arg name="last2">Hawkins<space/></arg></template></extension><space/>Death is common in the first week<extension extension_name='ref' name="Archer &amp; Wall 2003"><template><target>cite journal</target><arg name="author">Archer H, Wall R<space/></arg><arg name="title">Acute haemorrhagic leukoencephalopathy: two case reports and review of the literature<space/></arg><arg name="journal">J. Infect.<space/></arg><arg name="volume">46<space/></arg><arg name="issue">2<space/></arg><arg name="pages">133–7<space/></arg><arg name="date">February 2003<space/></arg><arg name="pmid">12634076<space/></arg><arg name="doi"><space/>10.1053/jinf.2002.1096</arg><arg name="url">http://linkinghub.elsevier.com/retrieve/pii/S0163445302910960</arg><arg name="last2">Wall<space/></arg></template></extension><space/>and overall mortality is about 70%,<extension extension_name='ref' name="Davies et al. 2006"></extension><space/>but increasing evidence points to favorable outcomes after aggressive treatment with corticosteroids, immunoglobulins, cyclophosphamide, and plasma exchange.<extension extension_name='ref' name="Tenembaum et al. 2007"></extension><space/>About 70% of survivors show residual neurological deficits,<extension extension_name='ref' name="Stone &amp; Hawkins 2007"></extension><space/>but some survivors have shown surprisingly little deficit considering the magnitude of the white matter affected.<extension extension_name='ref' name="Archer &amp; Wall 2003"></extension></paragraph><paragraph>This disease has been occasionally associated with<space/><link><target>ulcerative colitis</target></link><space/>and<space/><link><target>Crohn's disease</target></link>,<space/><link><target>malaria</target></link>,<extension extension_name='ref' name="Venugopal2013"><template><target>cite journal</target><arg name="author"><space/>Venugopal V, Haider M<space/></arg><arg name="year"><space/>2013<space/></arg><arg name="title"><space/>First case report of acute hemorrhagic leukoencephalitis following ''Plasmodium vivax'' infection<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Indian J Med Microbiol<space/></arg><arg name="volume"><space/>31<space/></arg><arg name="issue"><space/>1</arg><arg name="pages"><space/>79–81<space/></arg><arg name="doi"><space/>10.4103/0255-0857.108736<space/></arg><arg name="pmid"><space/>23508437<space/></arg><arg name="last2"><space/>Haider<space/></arg></template></extension><space/><link><target>septicemia</target></link><space/>associated with immune complex deposition,<space/><link><target>methanol</target></link><space/>poisoning, and other underlying conditions. Also anecdotal association with MS has been reported<extension extension_name='ref'>Yildiz O. et al. Acute hemorrhagic leukoencephalitis (Weston-Hurst syndrome) in a patient with relapse-remitting multiple sclerosis. J Neuroinflammation. 2015 Sep 17;12(1):175. doi: 10.1186/s12974-015-0398-1.</extension></paragraph><heading level='2'>Experimental allergic encephalomyelitis</heading><paragraph><template><target>main</target><arg>Experimental autoimmune encephalomyelitis</arg></template>Experimental allergic encephalomyelitis (EAE) is an animal model of CNS inflammation and demyelination frequently used to investigate potential MS treatments.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Rivers TM, Schwentker FF<space/></arg><arg name="title">Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys<space/></arg><arg name="journal">J. Exp. Med.<space/></arg><arg name="volume">61<space/></arg><arg name="issue"><space/>5</arg><arg name="pages">689–701<space/></arg><arg name="year">1935<space/></arg><arg name="doi">10.1084/jem.61.5.689<space/></arg><arg name="pmid">19870385<space/></arg><arg name="pmc">2133246</arg><arg name="last2">Schwentker<space/></arg></template></extension><space/>An acute monophasic illness, EAE is far more similar to ADEM than MS.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Sriram S, Steiner I<space/></arg><arg name="title">Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis<space/></arg><arg name="journal">Ann. Neurol.<space/></arg><arg name="volume">58<space/></arg><arg name="issue">6<space/></arg><arg name="pages">939–45<space/></arg><arg name="date">December 2005<space/></arg><arg name="pmid">16315280<space/></arg><arg name="doi">10.1002/ana.20743<space/></arg><arg name="url"></arg><arg name="last2">Steiner<space/></arg></template></extension></paragraph><heading level='2'>See also</heading><list type='bullet'><listitem><link><target>Optic neuritis</target></link></listitem><listitem><link><target>Transverse myelitis</target></link></listitem></list><heading level='2'>References</heading><paragraph><template><target>reflist</target><arg>2</arg></template></paragraph><heading level='2'>External links</heading><list type='bullet'><listitem><link type='external' href='http://www.myelitis.org/adem.htm'>Acute Disseminated Encephalomyelitis (ADEM)</link><space/>at myelitis.org</listitem><listitem><template><target>Office of Rare Diseases</target><arg>8639</arg><arg>Acute disseminated encephalomyelitis</arg></template></listitem><listitem><template><target>NINDS</target><arg>acute_encephalomyelitis</arg><arg>Acute Disseminated Encephalomyelitis Information Page</arg></template></listitem><listitem><link type='external' href='http://www.gosh.nhs.uk/medical-conditions/search-for-medical-conditions/acute-disseminated-encephalomyelitis/acute-disseminated-encephalomyelitis-information/'>Information for parents about Acute disseminated encephalomyelitis</link></listitem></list><paragraph><template><target>Multiple sclerosis</target></template><template><target>Diseases of the nervous system</target></template></paragraph><paragraph><link><target>Category:Multiple sclerosis</target></link><link><target>Category:Autoimmune diseases</target></link><link><target>Category:Neurological disorders</target></link><link><target>Category:Enterovirus-associated diseases</target></link><link><target>Category:Measles</target></link></paragraph></article>